# Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

> **NCT05665062** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Synthekine** · enrollment: 36 (estimated)

## Conditions studied

- CLL/SLL
- NHL
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Large B-cell Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** SYNCAR-001
- **DRUG:** STK-009
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05665062
- **Lead sponsor:** Synthekine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-23
- **Primary completion:** 2026-06-24
- **Final completion:** 2026-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665062, "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05665062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*